The Centers for Medicare and Medicaid Services will not move ahead with its proposal to “codify” an existing policy of reimbursing some Medicare Part B drugs approved by the US Food and Drug Administration under the 505(b)(2) pathway as multiple source products, which generally get lower payments than single source drugs.
“We appreciate [stakeholders’] concerns about implementing the proposals and requests for additional time for further evaluation and engagement,” CMS announced...








